California investment firm Vivo Capital has secured $740 million in commitments to be aimed at preclinical- and ...

GE HealthCare has obtained the FDA’s blessing for its latest imaging system combining SPECT and CT scanning, as well as for ...

Roche is rolling out a new diagnostic test to help assess hidden liver fibrosis in patients showing signs of metabolic ...

Charles River CEO James Foster had previously attributed the 2024 revenue dip to decreased demand from biopharma clients. In ...

CRISPR Therapeutics has reported reductions in triglycerides and LDL cholesterol of more than 80% after a single dose of its ...

Neurocrine Biosciences has handed back two discovery-stage gene therapy programs to Voyager Therapeutics, although the ...

Mersana Therapeutics only has eyes for Emi-Le. Seeking to extend its cash runway into mid-2026, the biotech is laying off 55% ...

Marea Therapeutics has linked its lead candidate to a 53% placebo-adjusted mean reduction in remnant cholesterol, positioning ...

The National Institutes of Health (NIH) has laid off 250 more employees, with this round of cuts hitting 50 workers at the ...

Beacon Therapeutics may have found a guiding light in a disease area where other companies have stumbled with its ...

C4 Therapeutics is sawing off another part of its solely owned pipeline, this time ending work on its clinical-stage BRAF ...

Vertex Pharmaceuticals is pressing pause on a phase 1/2 cystic fibrosis (CF) trial over a tolerability issue while reporting ...